



Retrophin to Fund Research Program at The Hospital for Sick Children ("SickKids®")

November 4, 2013

New York, NY (November 4, 2013) - Retrophin, Inc. (OTCQB: RTRX) today announced that it will provide funding, over a three-year term, to The Hospital for Sick Children ("SickKids®"), Canada's largest pediatric academic health sciences center, in support of its study entitled, "Carrier Mediated Delivery of Therapeutic Proteins into the Brain." The Company's funding to SickKids will be matched by Brain Canada, as part of a Multi-Investigator Research Initiative Grant.

In consideration of its support, Retrophin will receive the exclusive option to all licensable intellectual property ("IP") emanating from the study, including the right to utilize such IP for the potential development of treatments that may include Rett Syndrome, Fragile X Syndrome, Spinal Muscle Atrophy, Purine Nucleoside Phosphorylase ("PNP")-Deficiency or Canavan Disease. Financial terms of the agreement were not disclosed.

Commenting on today's news, Martin Shkreli, Founder, President and Chief Executive Officer of Retrophin, noted, "We are honored to be able to support SickKids' esteemed research team in this important study, aimed at developing a new method of delivering therapeutic compounds to the brain. We are hopeful that the results of the study will allow Retrophin to pursue the development of novel new therapies for several serious, rare and debilitating childhood diseases."

About Brain Canada

Brain Canada is the successor to NeuroScience Canada, a national, charitable organization that develops and supports collaborative, multidisciplinary, multi-institutional research across the neurosciences. Through partnering with the public, private and voluntary sectors, Brain Canada connects the knowledge and resources available in this area to accelerate neuroscience research and funding, and maximize the output of Canada's world-class scientists and researchers. In 2006, NeuroScience Canada received the Conference Board of Canada/Spencer Stuart non-profit National Award in Governance.

About The Hospital for Sick Children

The Hospital for Sick Children (SickKids) is recognized as one of the world's foremost pediatric health-care institutions and is Canada's leading center dedicated to advancing children's health through the integration of patient care, research and education. Founded in 1875 and affiliated with the University of Toronto, SickKids is one of Canada's most research-intensive hospitals and has generated discoveries that have helped children globally. Its mission is to provide the best in complex and specialized family-centered care; pioneer scientific and clinical advancements; share expertise; foster an academic environment that nurtures health-care professionals; and champion an accessible, comprehensive and sustainable child health system. SickKids is proud of its vision for Healthier Children. A Better World. For more information, please visit www.sickkids.ca.

About Retrophin

Retrophin is a pharmaceutical company focused on the discovery and development of drugs for the treatment of debilitating and often life-threatening diseases for which there are currently no viable patient options. The Company is currently focused on several catastrophic diseases affecting children, including Focal Segmental Glomerulosclerosis (FSGS), Pantothenate Kinase-Associated Neurodegeneration (PKAN) and Duchenne Muscular Dystrophy. Retrophin's lead compound, RE-021, is scheduled to begin enrollment in a potentially pivotal Phase 2 clinical trial for the treatment of FSGS during 2013. For additional information, please visit www.retrophin.com.

Forward-Looking Statements

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of pharmaceutical products. Without limiting the foregoing, these statements are often identified by the words "may", "might", "believes", "thinks", "anticipates", "plans", "expects", "intends" or similar expressions. In addition, expressions of our strategies, intentions or plans are also forward-looking statements. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect the Company's business. You are cautioned not to place undue reliance on these forward-looking statements as there are important factors that could cause actual results to differ materially from those in forward-looking statements, many of which are beyond our control. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Investors are referred to the full discussion of risks and uncertainties as included in the Company's filings with the Securities and Exchange Commission.

###

Retrophin, Inc.
Marc Panoff, 917-261-3684
CFO
marc@retrophin.com
or
Investors
Rx Communications Group
Paula Schwartz, 917-322-2216
pschwartz@rxir.com

Source: Retrophin, Inc.

News Provided by Acquire Media